---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-223656"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2021-07-26T23:59:59+00:00"
generated_at: "2026-06-30T02:35:33.557961+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics appoints Kristian Humer as CFO and CBO, effective July 26, 2021

## Summary
- Mr. Humer will receive an annual base salary of $530,000, a sign-on bonus of $400,000, and a target bonus of 45% of base salary.
- He received an initial equity grant of options to purchase 360,000 shares, vesting over four years.
- Mr. Humer previously served as Managing Director in the Global Healthcare team at Citigroup Inc.
- The inducement grant was approved by a majority of independent directors in accordance with Nasdaq Listing Rule 5635(c)(4).

## SEC filing metadata
- accession: 0001193125-21-223656
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2021-07-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312521223656/0001193125-21-223656-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312521223656/d182412d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-223656
- JSON: https://secwatch.observer/filing/0001193125-21-223656.json
- Plain text: https://secwatch.observer/filing/0001193125-21-223656.txt

## Key facts
- Executive change
  Kristian Humer was appointed as Chief Financial Officer and Chief Business Officer at Viridian Therapeutics, Inc.\DE.
  - Action: appointed
  - Role: Chief Financial Officer and Chief Business Officer
  source text: On July 26, 2021, Viridian Therapeutics, Inc. (the “Company”) announced the appointment of Kristian Humer as the Company’s Chief Financial Officer and Chief Business Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312521223656/0001193125-21-223656-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.